Skip to main content
. Author manuscript; available in PMC: 2017 Feb 15.
Published in final edited form as: Int J Cancer. 2015 Sep 22;138(4):843–852. doi: 10.1002/ijc.29834

Table 3.

Hazard ratios and 95% confidence intervals for the association between cumulative average physical activity during premenopausal and postmenopausal periods and incident epithelial ovarian cancer in Nurses’ Health Study (1986–2010) and Nurses’ Health Study II (1989–2011)

Physical activity in MET-hours/week, HR (95% CI)
<3 3 – <9 9 – <18 18 – <27 ≥27
Premenopausal physical activity
All cases (N=462)
 Cases, n 74 100 120 60 108
 Age-adjusted 1.31 (0.97, 1.78) 1.00 (ref) 1.24 (0.95, 1.61) 1.07 (0.77, 1.47) 1.48 (1.12, 1.95)
 Multivariable1 1.30 (0.96, 1.76) 1.00 (ref) 1.23 (0.94, 1.60) 1.04 (0.76, 1.44) 1.43 (1.09, 1.89)
 Multivariable + BMI 1.29 (0.95, 1.75) 1.00 (ref) 1.24 (0.95, 1.63) 1.06 (0.77, 1.47) 1.50 (1.13, 1.97)
Premenopausal cases (N=209)
 Cases, n 30 42 52 26 59
 Age-adjusted 1.35 (0.84, 2.18) 1.00 (ref) 1.19 (0.79, 1.79) 1.03 (0.63, 1.68) 1.60 (1.07, 2.39)
 Multivariable2 1.34 (0.83, 2.16) 1.00 (ref) 1.16 (0.77, 1.75) 0.99 (0.61, 1.62) 1.51 (1.01, 2.26)
 Multivariable + BMI 1.32 (0.81, 2.12) 1.00 (ref) 1.19 (0.79, 1.80) 1.04 (0.64, 1.71) 1.66 (1.11, 2.49)
Postmenopausal cases (N=253)
 Cases, n 44 58 68 34 49
 Age-adjusted 1.29 (0.87, 1.92) 1.00 (ref) 1.29 (0.90, 1.84) 1.14 (0.74, 1.75) 1.38 (0.93, 2.03)
 Multivariable3 1.26 (0.85, 1.88) 1.00 (ref) 1.28 (0.90, 1.83) 1.10 (0.72, 1.69) 1.35 (0.92, 1.99)
 Multivariable + BMI 1.25 (0.84, 1.86) 1.00 (ref) 1.28 (0.89, 1.82) 1.09 (0.71, 1.68) 1.34 (0.91, 1.99)
Postmenopausal physical activity
Postmenopausal cases (N=574)
 Cases, n 77 138 148 101 110
 Age-adjusted 1.07 (0.80, 1.41) 1.00 (ref) 1.02 (0.81, 1.29) 1.20 (0.93, 1.56) 1.04 (0.81, 1.34)
 Multivariable3 1.07 (0.81, 1.42) 1.00 (ref) 1.01 (0.80, 1.28) 1.18 (0.91, 1.53) 1.03 (0.80, 1.33)
 Multivariable + BMI 1.05 (0.79, 1.40) 1.00 (ref) 1.02 (0.80, 1.28) 1.18 (0.91, 1.53) 1.03 (0.80, 1.33)
1

Stratified by age, calendar years and cohort, and adjusted for menopausal status at ovarian cancer diagnosis, duration of OC use, parity, history of tubal ligation, history of hysterectomy, duration of PMH use by type, family history of breast or ovarian cancer, cumulative average intake of lactose and caffeine

2

Accounted for the variables in 1 except menopausal status at ovarian cancer diagnosis and duration of PMH use by type

3

Accounted for the variables in 1 except menopausal status at ovarian cancer diagnosis

HHS Vulnerability Disclosure